Inspire Medical Systems Inc has filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to a proposed initial public offering (IPO) of its common stock. Inspire Medical is a medical technology company that makes an implantable therapy for obstructive sleep apnea (OSA) and is focused on the development and commercialization of innovative and minimally invasive solutions for patients with OSA.

The number of shares to be offered and the price range for the offering have not yet been determined. Inspire has applied to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.”

BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint lead book-running managers for the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as comanagers for the proposed offering.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from any of the following sources:

  • BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: dg.prospectus_requests[at]; or
  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny[at]

A registration statement on Form S-1 relating to these securities has been filed with the US Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.